Thrombolytic treatment in acute myocardial infarction achieves coronary patency in most patients.' Mortality in groups treated early after the onset of symptoms is significantly reduced,' but left ventricular function does not always improve. 5 Myocardial necrosis during the period of vessel occlusion is partly responsible for the irreversible ventricular impairment that occurs even when the vessel is re-opened. In the dog the expanding area of myocardial necrosis induced by experimental coronary occlusion is surrounded by a potentially viable ischaemic zone.6 But viable ischaemic cells can be irreversibly damaged when coronary flow is reestablished. During reperfusion, molecular oxygen is converted to oxygen metabolites, which are toxic and can promote further tissue injury. In this way, reoxygenation of the myocardium may itself result in secondary deterioration in myocardial function-the "oxygen paradox".7 In animal models the extent of injury is reliably reduced and residual myocardial function appreciably improved by agents that either suppress the generation of oxygen derived free radicals or inhibit the damaging effects that these reactive oxygen metabolites produce. 8 Direct evidence of injury by free radicals has yet to be shown in the human heart, but many studies of other mammals have linked reactive oxygen metabolites with myocardial injury. Many workers conclude from these studies that interventions directed against free radicals will improve myocardial function after thrombolysis for acute infarction and in other forms of myocardial revascularisation (coronary bypass graft surgery and coronary angioplasty) and during cardiac transplantation. Appreciation of such studies depends on an understanding of some simple biochemistry.
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BIOCHEMISTRY OF OXYGEN AND ITS FREE RADICALS
A free radical is an atom, ion, or molecule with one or more unpaired electrons. This configuration leads to an increased reactivity with other molecules. The amount of reactivity depends on the ease with which a species can accept electrons (is reduced) or donate them (is oxidised).
During aerobic metabolism molecular oxygen (02) acts as the terminal electron acceptor and undergoes stepwise reduction to water. Oxygen is a bi-radical: it has two unpaired electrons in separate, parallel orbits both spinning in the same direction.9 Non-radical species have paired electrons spinning in opposite directions. One of these must spin invert before both can be accepted by oxygen. This process can occur, but limits the reactivity of molecular oxygen, which preferentially accepts electrons one at a time (univalent reduction). The univalent reduction of oxygen produces the superoxide anion radical (02--) Equation (1)02 + e-. 02-In this equation, the dot (.) represents an unpaired electron and signifies a free radical.
The superoxide anion is comparatively unreactive. It has a very short halflife and i-s solubility in lipids is low. These properties limit its capacity to diffuse away from its site of generation and to affect cell membranes. In an ischaemic environment with acid pH, the anion will become protonated forming the more reactive perhydroxyl radical (HO2 ( and at other biological sites), the cytosolic enzyme xanthine oxidase is normally present in a dehydrogenase form, using nicotinamide adenine dinucleotide (NAD+) as an electron acceptor, for the conversion of the purines, hypoxanthine and xanthine, to uric acid. During ischaemia, the dehydrogenase form is converted to the true oxidase form, which uses oxygen, instead of NAD+, as electron acceptor. On reperfusion of ischaemic tissue, the delivered oxygen can be reduced by this system, producing superoxide anion radical and hydrogen peroxide. '4 In the myocardium the xanthine oxidase system could be an important source of free radicals," but recent work suggesting that proteolytic conversion into the true oxidase form is rather slow in the heart'6 makes this less likely.
Other sources offree radicals In addition to the respiratory burst of neutrophils and the cytosolic xanthine oxidase/dehydrogenase system, other important intracellular sources of free radical production include the mitochondria, the endoplasmic reticulum, and the peroxisome. During ischaemia, components of the mitochondrial electron transport chain become reduced. On re-oxygenation, single electron reduction of oxygen is then more likely and results in increased superoxide production. In addition, enzyme catalysed demethylation and hydroxylation, which are usually coupled to the reduction of NAD(P)H, may become uncoupled after transient ischaemia. Oxygen is then reduced instead of NAD(P)H, with resultant superoxide generation. '7 Finally, free radicals may be generated in association with the arachidonic acid cascade. It may be relevant that during ischaemia, activation of phospholipase increases the release of arachidonate. '8 It can be seen that normal cellular metabolism can result in free radical generation and that these intracellular sources may be enhanced during a short lived ischaemic episode. During such adverse conditions normal tissue protection against auto-oxidative tissue damage may be impaired. But the finding of lipid peroxidation in association with a particular disease state cannot be used to implicate free radical damage as a direct cause of the disease process, because tissues damaged by any mechanism will peroxidise (go rancid) more rapidly than healthy tissue. 23 Free radical damage to proteins, and especially immunoglobulins, may also be measured, and recently the technique of electron-spin resonance spectroscopy has permitted identification of a free radical in whole tissue, by measurement of the magnetic moment resulting from the spin of its unpaired electron.'
In anaesthetised dogs regional myocardial ischaemia may be induced by ligation of a coronary artery. In these circumstances, concentrations of malondialdehyde (a product of lipid peroxidation) in the coronary venous blood gradually increase with time, reaching a peak at three hours. At the same time, electron-spin resonance spectroscopy of the ischaemic myocardium shows oxygen free radical production. There is depletion ofnaturally occurring antioxidants, such as alpha-tocopherol (vitamin E) and ascorbate (vitamin C), and ofthe enzyme scavengers superoxide dismutase, catalase, and the selenoenzyme glutathione peroxidase.2' Several recent studies that used a xanthine oxidase/purine system to generate free radicals have confirmed, at least in the rat, the detrimental effects of free radicals on the normal myocardium. There is both reduced contractility' and ultrastructural change, including swelling of myocytes and endothelial cells, with intracellular disruption.27 Superoxide dismutase and catalase,'7 and antioxidants'2 have considerable cardioprotective effects.
In animal models, agents that scavenge free radicals may reduce ischaemic injury. Pre-treatment with allopurinol reduces the calculated ischaemic volume below mid-left anterior descending artery ligation,'9 and inhibits ischaemic (and reperfusioninduced) arrhythmias.5303' While the mechanism of benefit may be a reduction in free radical generation via inhibition of xanthine oxidase, allopurinol is also a direct scavenger of the hydroxyl radical. However, a vasodilator effect, and maintenance of the nucleotide pool by allopurinol, have also been suggested as possible cardioprotective mechanisms.
Many groups using a range of animal reperfusion models have' shown highly significant cardioprotective effects by free radical scavengers such as mannitol (an hydroxyl radical scavenger), scavenging enzymes, antioxidants, and iron chelators such as desferrioxamine. Benefit has been assessed mainly in terms of reduction in infarct size and an improvement in ventricular function in treated as compared with untreated control groups. Appreciable reduction of infarct size was shown by histological and autoradiological techniques,3234 which estimate the percentage ofthe "at risk" myocardium that becomes infarcted, and by reduction in creatinine kinase release.35 '3 Striking improvement in ventricular function, assessed by preservation of developed pressure (dP) and dP/dt max, reduction in end diastolic pressure, and preservation of systolic wall thickening, are also seen in treated groups3739 Furthermore, the beneficial effects of agents that oppose free radicals are associated with a reduction in free radical production measured directly by electron-spin resonance spectroscopy and indirectly by lipid peroxidation. At the same time, energy stores are increased in the treated, reperfused myocardium. '6 The studies showing most improvement were of treatment started before the onset of ischaemia. In clinical situations if treatment is started later during the ischaemic period immediately before reperfusion it may be less beneficial. Furthermore, some studies suggest that intervention directed against free radicals may only delay rather than prevent myocyte necrosis.'
CONCLUSION
The complexity of free radical generation and interaction provides several potential therapeutic targets, and a combined approach that uses xanthine oxidase inhibitors, antioxidants, radical scavengers, and metal chelators is most likely to reduce myocardial reperftision injury mediated by free radicals in man. Xanthine oxidase inhibitors, allopurinol and oxypurinol, and antioxidants are available. Both recombinant human superoxide dismutase and selenium-based glutathione peroxidase analogues are being developed, and chelators with greater specificity for iron, and which lack the ocular toxicity of desferrioxamine, are being evaluated in animals.
Although free radicals have been implicated in many injurious processes,8202" it should be borne in mind that they may also have a beneficial role.
Reactive oxygen metabolites are known to be important in our natural defence against infection, and may well also initiate tissue repair by, for example, promoting fibroblast proliferation.'4 Clearly this might be relevant in myocardial scar formation after an infarct. The future for free radical modification in human heart disease is exciting, but the way forward must lie in careful identification and elucidation offree radical mechanisms in reperfusion injury in man. Only then should suitably controlled clinical trials proceed. We believe that the temptation to administer a theoretically harmless "anti-free radical" cocktail together with thrombolytic treatment for acute myocardial infarction is not yet justified. 
